"The Middle East, and the Gulf region in particular, is ready for MBOs. With increasing pressure on family-owned businesses and governments to thrive in the global economy, private equity vendors may ...
On Monday, the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for Monogram Technologies Inc.’s (NASDAQ:MGRM) Monogram mBôs TKA System. Ben Sexson, Monogram’s Chief Executive Officer, ...
FDA Decision is Expected Within 90 Days of Initial Submission; However, the Process May be Paused if Additional Information is Requested AUSTIN, TX / ACCESSWIRE / August 8, 2024 / Monogram ...
Company to Conduct Clinical Trial to Produce Additional Information Within 180 Days AUSTIN, TX / ACCESSWIRE / October 2, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), ...
This article is brought to you by our exclusive subscriber partnership with our sister title USA Today, and has been written by our American colleagues. It does not necessarily reflect the view of The ...
Company has Completed all Supplemental Testing and has Submitted its Formal Response to the FDA's Additional Information Request (AIR) Investigator Meeting and Clinical Trial Training Held at the ...
We’ll send you a myFT Daily Digest email rounding up the latest Asia news every morning. Management buy-outs are fraught with conflicts of interest anywhere. In Japan, MBOs take these risks to even ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results